ND4 COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN INTHE TREATMENT OF POST-HERPETIC NEURALGIA IN SCOTLAND  by Dakin, HA et al.
patients in the Swedish MS registry for the Stockholm County.
Patients withdrawing from treatment in both arms were assumed
to follow the disease course of 824 patients with relapsing-
remitting disease at onset in the natural history cohort in
Ontario, Canada. Costs and utilities by level of disease severity
are based on a recent observational study in 1339 Swedish
patients. All data sets were available at patient-level. Main re-
sults are presented for the societal perspective, over a 20-year
time frame, in 2005 Euro (1€ = 9.25SEK) discounted at 3%.
RESULTS: In the base case, treatment with natalizumab was less
expensive and more effective than treatment with current DMDs
in Sweden, i.e. it dominated standard therapy. When only health
care costs were considered, the cost per QALY gained with
natalizumab was €38,145. Health effects are sensitive only to the
time horizon of the analysis, and assumptions about effective-
ness of natalizumab beyond the trial. CONCLUSION: This
cost-effectiveness analysis used registry data, cohort and obser-
vational studies to extrapolate the efﬁcacy ﬁndings of natali-
zumab from the AFFIRM clinical trial to measure effectiveness
in clinical practice. The analysis results suggest that for the
population considered, natalizumab provides an additional
health beneﬁt at a similar cost to current DMDs from a societal
perspective.
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OBJECTIVES: Markov modeling has been widely used to
assess the cost-effectiveness of disease modifying drugs (DMDs)
in patients with relapsing form of multiple sclerosis (RFMS). Its
limitations, along with variations in disease progression, often
lead to unrealistic clinical assumptions and oversimpliﬁcation
of the course of RFMS. This study assessed the reliability of
modeling clinical outcomes for patients receiving interferon-
beta-1a (IFNb1a) subcutaneously (SC) versus intramuscularly
(IM) using discrete event simulation (DES). METHODS: The
model creates a cohort of individual patients by reading in
actual patient proﬁles and “cloning” them-one receives IFNb1a
SC, and the other IM. Patients may suffer relapses, develop new
T2 lesions, experience adverse events, stop treatment, progress
to secondary progressive MS or die. Time for each event is
sampled from failure time distributions speciﬁed by the indi-
vidual’s risk proﬁle. When a relapse occurs, an actual relapse
proﬁle comprising severity and recovery status is assigned and
processed accordingly. Model inputs were mostly derived from
the EVidence of Interferon Dose-response European North
American Comparative Efﬁcacy (EVIDENCE) trial with a few
from published literature. Results based on 100 replications of
10,000 patient pairs were validated against the trial results.
RESULTS: Predictions at 64 weeks, the mean follow-up of the
EVIDENCE trial, were similar to the trial RESULTS: Fifty-four
percent vs. 56% (model vs. trial) of SC and 45% vs. 48% of
IM users remained relapse-free and the annual relapse rate was
0.51 vs. 0.54 with SC and 0.66 vs. 0.65 with IM use. Of
relapses, 57% required no treatment, 36% an outpatient visit,
and 7% a hospital stay, almost identical to the trial results with
57%, 36%, and 8%, respectively. CONCLUSION: Use of DES
permits realistic modeling of DMDs in RFMS, use of actual
patient-level data, and avoided unrealistic assumptions, while
closely predicting the clinical outcomes with efﬁciency, ﬂexibil-
ity and transparency.
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OBJECTIVES: To assess the cost-effectiveness of the Versatis
lidocaine 5% medicated plaster relative to 300 and 600 mg/day
pregabalin in the treatment of post-herpetic neuralgia (PHN)
from the perspective of the Scottish National Health Service.
METHODS: The costs and beneﬁts of the three treatments were
assessed over a six-month time horizon using a Markov model.
The model structure allowed for differences in costs, utilities and
transition probabilities between the initial 30-day run-in period
and maintenance therapy and took account of add-in medication
and drugs received by patients discontinuing therapy. Transition
probabilities were based on clinical trials and Delphi panel
estimates. Resource use and add-in/switch medications were
obtained from 2 Delphi panels; cost data were from ofﬁcial price
tariffs. Published utilities were adjusted for age and were
supplemented/validated by a Delphi panel. Lidocaine-treated
patients were assumed to receive 1.03 plasters/day based on US
prescribing data. RESULTS: The average patient receiving the
lidocaine plaster accrued 0.292 quality-adjusted life-years
(QALYs) over six months—0.067 more than 300 mg pregabalin
and 0.061 more than 600 mg pregabalin. The total treatment
cost for patients receiving the lidocaine plaster (£681/patient)
was very similar to that for 300 mg pregabalin (£636/patient)
and 600 mg pregabalin (£655/patient). The lidocaine plaster cost
£674/QALY (95% conﬁdence interval [95% CI]: dominant,
£4,780) relative to 300 mg/day pregabalin and £434/QALY
(95% CI: dominant, £5,009) relative to 600 mg/day pregabalin.
Probabilistic sensitivity analysis demonstrated that we can be
99.9% conﬁdent that the lidocaine plaster is cost-effective rela-
tive to 300 mg pregabalin and 99.8% conﬁdent that it is cost-
effective relative to 600 mg pregabalin at a £20,000/QALY
threshold. The lidocaine plaster cost £27 per additional month
with sufﬁcient pain relief and no intolerable side-effects relative
to 300 mg pregabalin and £18/month relative to 600 mg pre-
gabalin. CONCLUSION: The Versatis lidocaine 5% medicated
plaster is a highly cost-effective alternative to pregabalin for the
treatment of PHN in Scotland.
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OBJECTIVES: The currently available formulations budesonide/
formoterol (BUD/FORM, Symbicort) and salmeterol/ﬂuticasone
(SAL/FLU, Seretide) have been shown to be effective in the treat-
ment of asthma. This study compared outcomes with BUD/
FORM and SAL/FLU in real-life practice. METHODS: Cohorts
of asthma patients initiated on BUD/FORM or SAL/FLU
between 2001 and 2006 were identiﬁed from IMS Disease Ana-
lyzer, a longitudinal UK database of physician records. Patients
were followed 12 months before and after treatment initiation
(TI). Treatment success was deﬁned as no oral corticosteroid
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